BioBio schreef op 25 september 2020 08:53:
Kijk aan wat hebben we hier? Persbericht Galapagos:
Galapagos reports that Gilead and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.
Onno hangt slingers op. Eens zien of de koers dat ook doet straks.